8189 — Tianjin Teda Biomedical Engineering Co Cashflow Statement
0.000.00%
- HK$832.42m
- HK$986.51m
- CNY385.48m
Annual cashflow statement for Tianjin Teda Biomedical Engineering Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -50 | -44.8 | -26.5 | -17.6 | -38.2 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 37.3 | 39.4 | 4.93 | 2.77 | 24.9 |
Discontinued Operations | |||||
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 41.5 | -10.7 | -6.64 | -9.95 | -22.1 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 36 | -6.68 | -12.8 | -13.2 | -26.3 |
Capital Expenditures | -6.12 | -27.6 | -8.8 | -2.47 | -2.56 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -20.4 | 19.1 | -4.13 | 2 | -34.7 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -26.5 | -8.51 | -12.9 | -0.467 | -37.2 |
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -20.2 | 28.1 | 6.17 | 12.7 | 83 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -10.7 | 12.9 | -19.6 | -0.893 | 19.4 |